Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
Conditions: Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | China Health | Databases & Libraries | Ovarian Cancer | Ovaries | Research